Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
复制标题
DOI：
10.1111/liv.13289
复制
发表时间：
2017-02
影响因子：
6.7
通讯作者：
Bin-Qiao Wang;Yong-Lin Wang;Ke-Qing Shi
中科院分区：
文献类型：
--
作者：
Bin-Qiao Wang;Yong-Lin Wang;Ke-Qing Shi
这意味着仅仅PVTT的程度不是决定治疗策略或治疗结果的唯一因素。例如，即使PVTT的范围局限于门静脉的第二分支，如果肿瘤是多发性/浸润性HCC，也不能用手术切除治疗。因此，应谨慎解释既往研究之间的治疗结局比较。同样，本研究的主要信息是，对于伴有PVTT的HCC患者，建议采用更高放射治疗剂量的放射治疗，而不是单药治疗，这似乎符合局部晚期癌症的肿瘤学原则。
means just the extent of PVTT is not the only factor to determine the treatment strategy or treatment outcomes. For instance, even though the extent of PVTT is confined to the second branch of portal vein, if the tumour is multiple/infiltrative HCCs, it cannot be treated with surgical resection. Therefore, the comparison of the treatment outcomes among the previous studies should be cautiously interpreted. Again, the main message of this study is that not a monotherapy but multimodality treatment with radiotherapy of higher radiotherapy dose is recommended for HCC patients with PVTT, which seems in accordance with oncologic principle for locally advanced cancer.